Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) CFO Brian W. Adams Sells 1,958 Shares

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) CFO Brian W. Adams sold 1,958 shares of the company’s stock in a transaction that occurred on Wednesday, January 12th. The stock was sold at an average price of $15.68, for a total value of $30,701.44. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

NASDAQ:TRHC traded down $0.11 during trading hours on Friday, hitting $15.02. The company had a trading volume of 217,565 shares, compared to its average volume of 299,156. The company has a quick ratio of 1.27, a current ratio of 1.35 and a debt-to-equity ratio of 5.15. The company has a 50-day moving average of $13.45 and a 200 day moving average of $27.21. Tabula Rasa HealthCare, Inc. has a 1 year low of $10.05 and a 1 year high of $69.31.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Thursday, November 4th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.15. The company had revenue of $86.60 million during the quarter, compared to analysts’ expectations of $88.54 million. Tabula Rasa HealthCare had a negative return on equity of 44.56% and a negative net margin of 27.37%. The firm’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.35) EPS. On average, research analysts expect that Tabula Rasa HealthCare, Inc. will post -1.75 earnings per share for the current year.

Several research analysts recently commented on the company. Piper Sandler reduced their price objective on Tabula Rasa HealthCare from $41.00 to $13.00 and set a “neutral” rating for the company in a research note on Friday, November 5th. Benchmark reduced their price objective on Tabula Rasa HealthCare from $55.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, November 9th. Jefferies Financial Group assumed coverage on Tabula Rasa HealthCare in a research note on Wednesday, December 1st. They issued a “hold” rating and a $13.00 price objective for the company. Zacks Investment Research raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating and set a $17.00 price objective for the company in a research note on Friday, January 7th. Finally, Royal Bank of Canada reduced their price objective on Tabula Rasa HealthCare from $70.00 to $23.00 and set an “outperform” rating for the company in a research note on Monday, November 8th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $27.80.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Spouting Rock Asset Management LLC grew its holdings in shares of Tabula Rasa HealthCare by 7.5% during the 2nd quarter. Spouting Rock Asset Management LLC now owns 4,888 shares of the company’s stock worth $244,000 after purchasing an additional 340 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Tabula Rasa HealthCare by 54.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,315 shares of the company’s stock worth $66,000 after purchasing an additional 462 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Tabula Rasa HealthCare by 6.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 8,825 shares of the company’s stock worth $441,000 after purchasing an additional 509 shares during the period. Redmond Asset Management LLC grew its holdings in shares of Tabula Rasa HealthCare by 7.5% during the 3rd quarter. Redmond Asset Management LLC now owns 10,605 shares of the company’s stock worth $278,000 after purchasing an additional 739 shares during the period. Finally, FORA Capital LLC purchased a new position in shares of Tabula Rasa HealthCare during the 2nd quarter worth $40,000. Institutional investors and hedge funds own 85.31% of the company’s stock.

About Tabula Rasa HealthCare

Tabula Rasa Healthcare, Inc is a healthcare technology company, which engages in the development of solutions designed for pharmacists, providers, and patients to optimize medication regimens. It operates through the following segments: CareVention HealthCare and MedWise HealthCare. The CareVention HealthCare segment provides services, PACE, which is a center for Medicare & Medicaid services, or CMS, sponsored program providing medical and social services.

Featured Story: What are high-yield dividend stocks?

Insider Buying and Selling by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.